Glycoprotein IIb/IIIa Inhibitor-Associated Thrombocytopenia: Clinical Predictors and Effect on Outcome

Publisher： Karger

E-ISSN： 1421-9751|102|4|184-187

ISSN： 0008-6312

Source： Cardiology, Vol.102, Iss.4, 2004-10, pp. : 184-187

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Quick Simple Method of Determining Platelet Aggregability following Glycoprotein IIb/IIIa Receptor Inhibitor Administration

By  

Cardiology, Vol. 91, Iss. 3, 1999-09 ,pp. : 156-160

Karger

Access to resources Recommend Favorite

A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes

By  

CARDIOVASCULAR THERAPEUTICS (ELECTRONIC), Vol. 34, Iss. 5, 2016-10 ,pp. : 330-336

John Wiley & Sons Inc

Access to resources Recommend Favorite

Characteristics, Treatment and Outcome of Patients with Non-ST-Elevation Acute Coronary Syndromes and Multivessel Coronary Artery Disease: Observations from PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy)

By  

Cardiology, Vol. 98, Iss. 4, 2003-01 ,pp. : 195-201

Karger

Access to resources Recommend Favorite

Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 3, 2015-09 ,pp. : 390-396

John Wiley & Sons Inc

Access to resources Recommend Favorite

Current Knowledge of the Platelet Glycoprotein IIb/IIIa Receptor Antagonists for the Treatment of Coronary Artery Disease

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 30, Iss. 3, 2004-11 ,pp. : 27-43

Karger

Access to resources Recommend Favorite